Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Cytokinetics (Nasdaq: CYTK) opened its annual Corporate Giving Program, inviting proposals from eligible U.S. non-profit 501(c)(3) organizations for 2026 grants.

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) opened its annual Corporate Giving Program, inviting proposals from eligible U.S. non-profit 501(c)(3) organizations for 2026 grants.

The program offers donations up to $20,000 per organization, focusing on cardiovascular health equity, science education, and essential services in the Bay Area and Greater Philadelphia. Application deadline is August 3, 2026.

Argus Jun 8 session

-5.01% close to close Open Argus

Details

News Market Reaction – CYTK

On Jun 8, the day this news came out, CYTK closed 5.01% below the previous close.

Data tracked by StockTitan Argus for the Jun 8 session.

Market Context

On Jun 8, the day this news came out, the stock closed 5.0% below the previous close. A negative rea...

Analysis

On Jun 8, the day this news came out, the stock closed 5.0% below the previous close. A negative reaction despite the community-focused nature of this announcement would fit a pattern where even constructive updates sometimes coincided with weakness, such as the -4.01% move on the MYQORZO EU launch. The program does not alter fundamentals, so selling could reflect broader positioning or sensitivity to non-core news. With shares still above the 200-day MA at $62.23, prior gains leave room for profit-taking on seemingly neutral headlines.

Key Figures

Max donation per grantee: $20,000 Application deadline: August 3, 2026

Max donation per grantee

$20,000

Individual charitable donations for qualified 501(c)(3) organizations

Application deadline

August 3, 2026

Deadline for Cytokinetics Corporate Giving Program proposals

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   EU launch update

   24h Move

   -4.0%

   Launch of MYQORZO in Germany following EU approval for oHCM.

2. May 27

   Conference participation

   24h Move

   -0.4%

   Management attendance at two major June healthcare investor conferences.

3. May 20

   Annual meeting notice

   24h Move

   -0.9%

   Announcement of date and logistics for annual stockholder meeting.

4. May 18

   Inducement grants

   24h Move

   +1.7%

   Equity inducement awards to 8 new employees under Nasdaq Rule 5635(c)(4).

5. May 14

   Scientific symposium

   24h Move

   +1.8%

   Announcement of third CLIMB symposium on muscle biology and treatment modalities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

501(c)(3)

1 terms

501(c)(3) regulatory

"donations up to $20,000 for qualified 501(c)(3) organizations in the United States"

A 501(c)(3) is a U.S. federal tax designation for organizations organized and operated for charitable, educational, religious, scientific or literary purposes, which exempts them from federal income tax and generally makes donations to them tax-deductible. Investors pay attention because the designation shapes how the organization raises money, what activities it can legally pursue (for example, limits on political lobbying), and how transparent and financially stable it must be—factors that affect risk, reputation, and potential partnerships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, science education and certain essential services for local and at-risk communities.

“At Cytokinetics, our commitment to the communities around us is as fundamental to our mission as the science we pursue,” said Diane Weiser, Cytokinetics’ Senior Vice President, Corporate Affairs. “Through this program, we are proud to support the non-profit organizations on the front lines of building a future where everyone has a fair chance at health and opportunity.”

The Cytokinetics Corporate Giving Program consists of individual charitable donations up to $20,000 for qualified 501(c)(3) organizations in the United States that are neither engaged, nor directly involved in the practice of healthcare. Specifically, the program will provide funding to organizations with initiatives focused on science education and certain essential services for local and at-risk communities in the San Francisco Bay Area and Greater Philadelphia Region. Additionally, it will support eligible organizations dedicated to health equity initiatives in cardiovascular disease across the United States. Applications may now be submitted online at https://www.cybergrants.com/Cytokinetics/corporate_giving_eligibility.

The deadline to apply for the Cytokinetics Corporate Giving Program is August 3, 2026. For more information on the program, including eligibility details, guidelines and specifics, visit https://cytokinetics.com/responsibility/grants-and-giving-programs/corporate-giving-program/.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS^® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the Cytokinetics (NASDAQ: CYTK) Corporate Giving Program announced on June 8, 2026?

The Cytokinetics Corporate Giving Program is an annual initiative providing charitable donations to eligible U.S. non-profit organizations. According to Cytokinetics, it supports cardiovascular health equity, science education, and essential services for local and at-risk communities through targeted grants aligned with the company’s corporate values.

How much funding is available per organization in the 2026 Cytokinetics (CYTK) Corporate Giving Program?

Each qualified organization may receive an individual charitable donation of up to $20,000. According to Cytokinetics, funding is reserved for eligible 501(c)(3) organizations that meet program criteria and focus areas, including cardiovascular disease health equity, science education, and essential services in specified regions.

What is the application deadline for the 2026 Cytokinetics (CYTK) Corporate Giving Program?

The application deadline for the 2026 Cytokinetics Corporate Giving Program is August 3, 2026. According to Cytokinetics, eligible U.S. non-profit organizations must submit proposals online by this date to be considered for funding within the program’s specified focus areas.

Which types of organizations are eligible for the Cytokinetics (CYTK) Corporate Giving Program in 2026?

Eligible applicants are qualified 501(c)(3) non-profit organizations in the United States not engaged in the direct practice of healthcare. According to Cytokinetics, these organizations must align with program priorities in cardiovascular health equity, science education, or essential community services in defined geographies.

What focus areas does Cytokinetics (CYTK) prioritize in its 2026 Corporate Giving Program?

The program prioritizes cardiovascular disease health equity, science education, and certain essential services for local and at-risk communities. According to Cytokinetics, essential services grants focus on the San Francisco Bay Area and Greater Philadelphia Region, while cardiovascular health equity initiatives are supported nationwide.

How can non-profits apply to the 2026 Cytokinetics (CYTK) Corporate Giving Program?

Non-profits can apply by submitting an online application through the designated CyberGrants portal. According to Cytokinetics, additional information on eligibility, guidelines, and program specifics is available on the company’s grants and giving programs webpage, which outlines all requirements before submitting a proposal.